Skip to content
Journal ArticleAge and ageing·Graded and published ·Last edited

Fatty Liver After 65: GLP-1 Starters Died Less Often

Graded Preliminary — health records of 87,860 older adults followed up to ten years; without random assignment, hidden differences between the groups remain possible.

Design
Retrospective cohort study
Participants
87,860
Duration
10 years
Funding
—
Key Insight

Older adults with fatty liver who started a GLP-1 drug died less often and had liver failure less often than similar people.


Older adults with fatty liver linked to metabolism died less often if they had started treatment with a GLP-1 drug. These medicines mimic a gut hormone. Their risk of dying was 45 percent lower than in similar people who did not start one. Liver failure was also less common, with a 28 percent lower risk. The researchers note that fatty liver is the leading cause of long-term liver disease in older adults.

The team searched health records from a large US network. They looked for people aged 65 or older with fatty liver and at least one risk factor for heart and metabolic disease. In all, 43,930 of them started a GLP-1 drug. Each was paired with a similar person who did not, average age almost 72. Follow-up lasted up to ten years. Hospital stays were slightly less frequent. Serious heart and blood vessel events showed no clear difference. Bone thinning without fractures and damage to the retina were more common.

The records cannot show that the drugs themselves extend life. Nobody was assigned a treatment at random. The groups may differ in ways the records do not capture.

Disclaimer: Research summaries are provided for informational purposes only and do not constitute medical advice. Always consult a qualified healthcare professional before making changes to your health routine.